細胞番号 : 細胞名
RCB0544 : MBT-2
update : 2023/01/11
|
| 細胞特性(Comment:英) | A mouse cell line derived from bladder cancer. |
| 細胞特性(日) | マウス膀胱癌由来細胞株。 |
| 細胞特性(寄託者記述:英) | |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| 使用条件(日) | 基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
Akaza, Hideyuki
|
| 寄託日 |
1990
|
| 動物種 |
mouse
< Mammals
|
| 採取組織 |
bladder
|
| 病名 |
transitional cell carcinoma
|
| 細胞分類 |
cancer
|
| メモ_1 |
Mycoplasma was eliminated with MC-210.
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_4660
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
|
Adherent cells
|
| 培地 |
|
RPMI1640 + 10% FBS
|
| 抗生物質 |
|
Free
|
|
継代方法 |
|
0.25% Trypsin
|
|
継代密度 |
|
1 : 8 split
|
| 継代・培地交換頻度 |
|
Subculture : 2 times/week
|
| 培養最適温度 |
|
37
℃
|
| 二酸化炭素濃度 |
|
5
%
|
| 凍結培地 |
|
Medium + 10% DMSO
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ |
|
(-)
|
| マウス系統検査 |
|
OK
|
| アイソザイム検査 |
|
LD, NP
|
| 画像情報 |
寄託時情報 | ロット情報 |
|
|
|
| 文献情報 |
Reference(英) |
8件
|
| Reference(日) |
0件
|
| 利用者成果(英) |
10件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
4756
Matzkin H, Rangel MC, Soloway MS.
In vitro study of the effect of hyperthermia on normal bladder cell line and on five different transitional cell carcinoma cell lines.
J Urol
1992
147(6):1671-4
PubMed ID: 1593718
DOI: 10.1016/s0022-5347(17)37675-9
|
|
4755
Brausi M1, Blatnik A, Soloway MS.
Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
Urology
1990
35(3):253-6
PubMed ID: 2316090
DOI: 10.1016/0090-4295(90)80044-n
|
|
4754
Hickey DP1, Brausi M, Blatnik AF, Soloway MS.
Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Urology
1987
30(5):484-7
PubMed ID: 3118551
DOI: 10.1016/0090-4295(87)90388-8
|
|
4753
Niell HB, Herrod HG, Blatnik AF, Soloway MS.
In vitro and in vivo activity of two second generation platinum analogs in murine bladder cancer.
J Urol
1985
134(2):399-402
PubMed ID: 3894702
DOI: 10.1016/s0022-5347(17)47186-2
|
|
4752
Nag S, Blatnik A, Soloway M.
Enhancement of high intensity Iodine-125 brachytherapy by cis-platinum in a murine bladder tumor model.
J Urol
1984
131(6):1225-8
PubMed ID: 6539386
DOI: 10.1016/s0022-5347(17)50877-0
|
|
4751
Crabtree WN, Soloway MS, Matheny RB Jr, Murphy WM.
Metastatic characteristics of four FANFT-induced murine bladder tumors.
Urology
1983
22(5):529-31
PubMed ID: 6649210
DOI: 10.1016/0090-4295(83)90235-2
|
|
4750
Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS.
In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.
J Urol
1982
127(6):1233-7
PubMed ID: 7087044
DOI: 10.1016/s0022-5347(17)54305-0
|
|
1443
Soloway, M S
Intravesical and systemic chemotherapy of murine bladder cancer.
Cancer Res
1977
37:2918-29
PubMed ID: 406041
|
| 利用者成果(英) |
|
13186
Huetter J, Gritzan U, Gutcher I, Doecke WD, Luetke-Eversloh MV, Golfier S, Roider HG, Frisk AL, Hunter J, Pow A, Drake A, Levine Z, Levy O, Azulay M, Barbiro I, Cojocaru G, Vaknin I, Kreft B, Roese L.
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).
Cancer Immunol Res
2020
PubMed ID: 32312711
DOI: 10.1158/2326-6066.CIR-19-0321
|
|
11603
Aoki N, Matsui Y.
Comprehensive Analysis of Mouse Cancer/Testis Antigen Functions in Cancer Cells and Roles of TEKT5 in Cancer Cells and Testicular Germ Cells.
Mol. Cell. Biol.
2019
PubMed ID: 31208979
DOI: 10.1128/MCB.00154-19
|
|
14361
Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC
J Thorac Oncol
2019
14(12):2152-2163
PubMed ID: 31470128
DOI: 10.1016/j.jtho.2019.08.009
|
|
7121
Kato S, Mori S, Kodama T.
A Novel Treatment Method for Lymph Node Metastasis Using a Lymphatic Drug Delivery System with Nano/Microbubbles and Ultrasound.
J Cancer
2015
6:1282-94
PubMed ID: 26640589
DOI: 10.7150/jca.13028
|
|
15665
Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H.
Nanoparticulation of BCG-CWS for application to bladder cancer therapy
J Control Release
2014
176:44-53
PubMed ID: 24389133
DOI: 10.1016/j.jconrel.2013.12.027
|
|
8207
Kaori Yoshino, Kaoru Saijo, Chikako Noro and Yukio Nakamura
Development of a simple method to determine the mouse strain from which cultured cell lines originated
Interdisciplinary Bio Central
2010
2:0014
DOI: 10.4051/ibc.2010.2.4.0014
|
|
8911
FAN You-ming, GAO Yu-qi, HUANG Jian, LIAO Wei-gong, CAI Ming-chun
Screening and identification of differentially expressed genes in hippocampus of mice during hypobaric hypoxic delayed preconditioning
Chinese Journal of Pathophysiology
2006
22:342-346
|
|
9046
Shin-ichi Kohno 1, Chenhong Luo, Fumi Goshima, Yukihiro Nishiyama, Tetsutaro Sata, Yoshinari Ono
Herpes Simplex Virus Type 1 Mutant HF10 Oncolytic Viral Therapy for Bladder Cancer
Urology
2005
66 (5), 1116-21
PubMed ID: 16286150
DOI: 10.1016/j.urology.2005.05.041
|
|
17468
Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y.
Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer
Med Electron Microsc
2004
;37(4):216-24
PubMed ID: 15614446
DOI: 10.1007/s00795-004-0247-2
|
|
2669
Shibata MA, Horiguchi T, Morimoto J, Otsuki Y
Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer.
J Gene Med
2003
5:219-31
PubMed ID: 12666188
DOI: 10.1002/jgm.335
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト